These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Lucas RM; Ponsonby AL; Dear K; Valery P; Pender MP; Burrows JM; Burrows SR; Chapman C; Coulthard A; Dwyer DE; Dwyer T; Kilpatrick T; Lay ML; McMichael AJ; Taylor BV; van der Mei IA; Williams D Neurology; 2011 Jul; 77(4):371-9. PubMed ID: 21753179 [TBL] [Abstract][Full Text] [Related]
10. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504 [TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus and disease activity in multiple sclerosis. Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080 [TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431 [TBL] [Abstract][Full Text] [Related]
13. The levels of soluble forms of CD21 and CD83 in multiple sclerosis. Karampoor S; Zahednasab H; Etemadifar M; Keyvani H J Neuroimmunol; 2018 Jul; 320():11-14. PubMed ID: 29759135 [TBL] [Abstract][Full Text] [Related]
14. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. Angelini DF; Serafini B; Piras E; Severa M; Coccia EM; Rosicarelli B; Ruggieri S; Gasperini C; Buttari F; Centonze D; Mechelli R; Salvetti M; Borsellino G; Aloisi F; Battistini L PLoS Pathog; 2013; 9(4):e1003220. PubMed ID: 23592979 [TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Lindsey JW; Hatfield LM; Vu T Eur J Neurol; 2010 Oct; 17(10):1263-9. PubMed ID: 20402753 [TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-encoded BART9 and BART15 miRNAs are elevated in exosomes of cerebrospinal fluid from relapsing-remitting multiple sclerosis patients. Mohammadinasr M; Montazersaheb S; Hosseini V; Kahroba H; Talebi M; Molavi O; Ayromlou H; Hejazi MS Cytokine; 2024 Jul; 179():156624. PubMed ID: 38692184 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients. Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647 [TBL] [Abstract][Full Text] [Related]
18. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Zivadinov R; Ramanathan M; Hagemeier J; Bergsland N; Ramasamy DP; Durfee J; Kolb C; Weinstock-Guttman B Mult Scler Relat Disord; 2019 Nov; 36():101388. PubMed ID: 31525628 [TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491 [TBL] [Abstract][Full Text] [Related]
20. Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray. Loebel M; Eckey M; Sotzny F; Hahn E; Bauer S; Grabowski P; Zerweck J; Holenya P; Hanitsch LG; Wittke K; Borchmann P; Rüffer JU; Hiepe F; Ruprecht K; Behrends U; Meindl C; Volk HD; Reimer U; Scheibenbogen C PLoS One; 2017; 12(6):e0179124. PubMed ID: 28604802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]